"Urate Oxidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of urate and unidentified products. It is a copper protein. The initial products decompose to form allantoin. EC 1.7.3.3.
| Descriptor ID |
D014503
|
| MeSH Number(s) |
D08.811.682.943
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Urate Oxidase".
Below are MeSH descriptors whose meaning is more specific than "Urate Oxidase".
This graph shows the total number of publications written about "Urate Oxidase" by people in this website by year, and whether "Urate Oxidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Urate Oxidase" by people in Profiles.
-
Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leuk Res. 2020 02; 89:106298.
-
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535.
-
The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2019 02; 184(4):684-688.
-
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol. 2012 Jul; 39(7):1450-7.
-
Rasburicase for hyperuricemia in hemolytic uremic syndrome. Pediatr Nephrol. 2012 Feb; 27(2):325-9.
-
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.
-
Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. Ann Rheum Dis. 2011 Jul; 70(7):1277-81.
-
Rasburicase improves hyperuricemia in infants with acute kidney injury. Pediatr Nephrol. 2010 Feb; 25(2):305-9.
-
Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose-6-phosphate dehydrogenase deficient patient. Pediatr Blood Cancer. 2008 Oct; 51(4):568.
-
Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan; 19(1):34-8.